February 2025
Immunovia AB published the company’s Full Year Report 2024 on Tuesday, February 25, 2025, at 8:30 am CET.
Place: Immunovia website
Place: Lund
Listen to Jeff Borcherding, Immunovia CEO and Norma Alonzo Palma, PhD, VP Clinical and Medical Affairs present additional study results and share implications of the study on March 24, 2025, at 3 pm CET.
The Immunovia AB share is, since 3 April 2018, traded on Nasdaq Stockholm. Immunovia has one class of shares. The Company has a registered share capital of SEK 1,131,579.05 allocated among 22,631,581 shares. The par value of the shares is SEK 0.05 per share.
Trading information Ticker on Nasdaq Stockholm: IMMNOV ISIN-code: SE0006091997 LEI-code: 549300KHWL6KK1XGUO81 The shares are registered by Euroclear Sweden.
If you have further questions, please contact our IR contact.
If you are interested in receiving our press releases and reports, please click on “Subscribe”.
